Results 21 to 30 of about 7,822 (173)
Cytokines in oncolytic virotherapy
Cytokine & Growth Factor Reviews, 2020 Tumors represent a hostile environment for the effector cells of cancer immunosurveillance. Immunosuppressive receptors and soluble or membrane-bound ligands are abundantly exposed and released by malignant entities and their stromal accomplices. As a consequence, executioners of antitumor immunity inefficiently navigate across cancer tissues and fail ...
Pol, Jonathan +4 more
openaire +3 more sources
Vaccines, 2020 Myxoma virus (MYXV) is the prototypic member of the Leporipoxvirus genus of the Poxviridae family of viruses. In nature, MYXV is highly restricted to leporids and causes a lethal disease called myxomatosis only in European rabbits (Oryctologous cuniculus)
Masmudur M. Rahman, Grant McFadden
doaj +1 more source
The Hitchhiker's Guide to Virotherapy
Oncotarget, 2012 In contrast to most other cancer therapies, early research with oncolytic viruses (OV) tended to use direct or intratumoural routes of administration, initially motivated by concerns that the major limitation of intravenous delivery would be immune attack against the viruses, whether by complement, cytokine or most critically neutralising antibodies ...
Donnelly, O +4 more
openaire +5 more sources
Personalized virotherapy in cancer
Aging, 2015 After decades of intensive research, pancreatic adenocarcinoma (PDAC) remains a highly lethal disease with a median survival time that does not exceed 6.5 months [1]. Since more than 80% of patients present with advanced metastatic disease, systemic chemotherapy remains the only treatment.
Cafferata Eduardo G +1 more
openaire +3 more sources
Oncolytic Virotherapy Trials—Letter [PDF]
Clinical Cancer Research, 2013 We would like to thank Prof. Harrington for his insightful commentary ([1][1]) regarding our article by Kanerva and colleagues ([2][2]). During 2007–2011, the Advanced Therapy Access Program (ATAP) provided a unique opportunity for patients to access a technology they would not otherwise have ...
Hemminki Akseli +3 more
openaire +2 more sources
Frontiers in Immunology, 2021 Immune checkpoint inhibitors such as anti-PD-1 have revolutionized the field of oncology over the past decade. Nevertheless, the majority of patients do not benefit from them.
Victor Cervera-Carrascon +21 more
doaj +1 more source
Oncolytic Viruses and the Immune System: The Dynamic Duo
Molecular Therapy: Methods & Clinical Development, 2020 Oncolytic viruses (OVs) constitute a new and promising immunotherapeutic approach toward cancer treatment. This therapy takes advantage of the natural propensity of most tumor cells to be infected by specific OVs.
Ana Lemos de Matos +2 more
doaj +1 more source
Oncolytic virotherapy for ovarian cancer [PDF]
Oncolytic Virotherapy, 2012 In the past two decades, more than 20 viruses with selective tropism for tumor cells have been developed as oncolytic viruses (OVs) for treatments of a variety of malignancies. Of these viruses, eleven have been tested in human ovarian cancer models in preclinical studies.
Li, Shoudong +4 more
openaire +4 more sources
Pharmaceutics, 2020 Complex dermal wounds represent major medical and financial burdens, especially in the context of comorbidities such as diabetes, infection and advanced age.
Jordan R. Yaron +10 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2021 Diffuse alveolar hemorrhage (DAH) is one of the most serious clinical complications of systemic lupus erythematosus (SLE). The prevalence of DAH is reported to range from 1 to 5%, but while DAH is considered a rare complication there is a reported 50–80%
Qiuyun Guo +13 more
doaj +1 more source